BIIB Oct 2024 145.000 put
| Previous close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.0000 |
| Ask | 1.7000 |
| Strike | 145.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.4500 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
Investor's Business DailyIs Eli Lilly Stock A Buy After Snagging Approval For A New Eczema Drug?
The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now?
GuruFocus.comState Street Corp's Strategic Acquisition of Biogen Inc Shares
On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 250,487 shares of Biogen Inc (NASDAQ:BIIB), a prominent player in the biotechnology industry. This transaction increased State Street Corp's total holdings in Biogen to 7,346,505 shares, reflecting a trade price of $193.84 per share. This move not only underscores the firm's strategic investment approach but also highlights its confidence in Biogen's future prospects.
Insider MonkeyBiogen (BIIB): Pioneering CNS Treatments and Future Growth Prospects
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Biogen (NASDAQ:BIIB) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatility that indicates how much the price of a […]
